- Home
- CIK vs NKTX Comparison
CIK vs NKTX Comparison
Compare CIK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- NKTX
- Stock Information
- Founded
- CIK 1987
- NKTX 2015
- Country
- CIK United States
- NKTX United States
- Employees
- CIK N/A
- NKTX N/A
- Industry
- CIK Finance/Investors Services
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CIK Finance
- NKTX Health Care
- Exchange
- CIK Nasdaq
- NKTX Nasdaq
- Market Cap
- CIK 158.7M
- NKTX 170.8M
- IPO Year
- CIK N/A
- NKTX 2020
- Fundamental
- Price
- CIK $2.93
- NKTX $2.47
- Analyst Decision
- CIK
- NKTX Strong Buy
- Analyst Count
- CIK 0
- NKTX 5
- Target Price
- CIK N/A
- NKTX $15.20
- AVG Volume (30 Days)
- CIK 115.4K
- NKTX 1.5M
- Earning Date
- CIK 01-01-0001
- NKTX 11-07-2024
- Dividend Yield
- CIK 9.03%
- NKTX N/A
- EPS Growth
- CIK N/A
- NKTX N/A
- EPS
- CIK N/A
- NKTX N/A
- Revenue
- CIK N/A
- NKTX N/A
- Revenue This Year
- CIK N/A
- NKTX N/A
- Revenue Next Year
- CIK N/A
- NKTX N/A
- P/E Ratio
- CIK N/A
- NKTX N/A
- Revenue Growth
- CIK N/A
- NKTX N/A
- 52 Week Low
- CIK $2.50
- NKTX $2.08
- 52 Week High
- CIK $3.19
- NKTX $16.24
- Technical
- Relative Strength Index (RSI)
- CIK 50.24
- NKTX 50.49
- Support Level
- CIK $2.90
- NKTX $2.19
- Resistance Level
- CIK $2.95
- NKTX $2.70
- Average True Range (ATR)
- CIK 0.03
- NKTX 0.15
- MACD
- CIK 0.00
- NKTX 0.03
- Stochastic Oscillator
- CIK 75.00
- NKTX 54.90
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations, and individuals.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.